IVFH INNOVATIVE FOOD HOLDINGS INC Insider Trading

CEO Schubert Gary buys 166,666 shares at $0.30; holdings rise to 532,569 shares as cluster of 4 insiders buy in 14 days

Schubert Gary, Chief Executive Officer, purchased 166,666 shares at $0.30 on 2026-01-06, increasing his holdings from 365,903 shares to 532,569 shares (+45.5%). The current stock price of $0.43 is down 81.7% from the 52-week high of $2.35, although the stock has recovered 28.4% over the past 30 days. The buy occurred as part of a broader cluster pattern: 3 other insiders also purchased shares within the same 14-day window, suggesting coordinated confidence at depressed valuation levels. Against a backdrop of recent quarterly net losses of $1.7M, flat annual revenue growth (-0.1%), and a tight market capitalization of $23.6M, the CEO's substantial share accumulation and multi-insider cluster purchase warrant close monitoring of whether this represents genuine operational recovery expectations or other considerations.

Director Schmulen Mark purchases 288.9K shares of IVFH at $0.30; holdings surge 512.7%; cluster of 3 other insiders buying within 14 days.

Schmulen Mark, a director, acquired 288,890 shares at $0.30 on 2026-01-06, increasing his holdings from 56,344 to 345,234 shares, a +512.7% increase. This transaction coincides with a broader insider cluster pattern: 3 other insiders also purchased shares within the past 14 days, suggesting coordinated appetite at these prices. The company is trading at $0.38 (current), down 83.8% from its 52-week high of $2.35, and recently reported negative net income of $-1.7M on revenue of $16.4M; however, the 30-day price movement shows +16.0% recovery from recent lows. The synchronized buying activity from multiple board members at depressed valuations—shortly before this price rebound—warrants examination of whether material information or strategic repositioning is driving the pattern.

Director Smith Denver Johnson buys 505,555 shares of IVFH at $0.30; stock down -83.8% from 52-week high; 3 other insiders also bought within 14 days.

Director Smith Denver Johnson purchased 505,555 shares at $0.30, increasing his holdings by 18.2% to 3,289,655 shares. This buy occurs while the stock trades at $0.38, down -83.8% from its 52-week high of $2.35, and follows a 30-day gain of +16.0% countered by a 90-day decline of -24.0%. Johnson's prior four trades at IVFH have been consistently well-timed at the 90-day mark, with three generating gains of 22.7%, 24.2%, and 19.3% respectively. Notably, the cluster pattern shows 3 other insiders also bought within the past 14 days, suggesting coordinated conviction at current depressed valuations. Fundamentally, the company reported net losses of $-1.7M on quarterly revenue of $16.4M with flat annual growth, presenting a backdrop of deteriorating financial performance.

Director Pappas James C buys 505,555 shares of IVFH at $0.30; holds 8.80M shares (8.8% larger). Cluster pattern with 3 other insiders in 14 days.

Director James C Pappas purchased 505,555 shares at $0.30 on 2026-01-06, increasing his holdings from 8.29M to 8.80M shares. This buy occurs within a cluster of 3 other insider purchases over the preceding 14 days, signaling synchronized management accumulation at current levels. Pappas's prior 4 trades at IVFH show strong timing: each generated positive 90-day returns (24.4%, 10.8%, 10.4%, and 11.6% respectively), establishing a demonstrated pattern of entry discipline at this ticker. The stock has declined 83.4% from its 52-week high of $2.35 but has recovered 11.4% in the past 30 days; the fundamentals remain weak with trailing net income of -$1.7M against revenue of $16.4M. The synchronized cluster buying by multiple insiders, combined with Pappas's historical accuracy on IVFH entries, suggests management views the current depressed valuation as attractive, though deteriorating annual revenue growth (-0.1%) and ongoing losses present material execution risk.

Director James C Pappas buys 156,250 shares of IVFH at $1.60 ($250,000); 3-insider cluster pattern in 14 days

Pappas James C, a director at Innovative Food Holdings Inc (IVFH), purchased 156,250 shares (156.2K shares) at $1.60 on 2024-12-09 for $250,000.00 ($250.0K), increasing his holdings to 8,290,675 shares (8.29M shares). His prior three purchases at IVFH over the past 13 months all delivered positive 90-day returns (10.8%, 14.4%, 10.4%, 11.6%, and 0.5% returns across the transactions), establishing a track record of well-timed entry points at this ticker. This current transaction is part of a cluster buy pattern—2 other insiders purchased within the past 14 days—signaling synchronized conviction among board and management. However, context demands caution: IVFH reported a negative full-year net income in its most recent fiscal period despite the latest quarterly net income of $1,334,830.00 ($1.3M), and annual revenue contracted 9.8% year-over-year, pointing to structural business headwinds that offset the positive entry-timing history.

Director Gramm Jefferson buys 1,250,000 shares of IVFH at $1.60 for $2,000,000; holdings rise 25.3% to 6.19M shares.

Gramm Jefferson, a Director, purchased 1,250,000 shares at $1.60 on 2024-12-04, increasing his stake by 25.3% to 6,193,349 shares—a substantial personal capital commitment of $2,000,000. This is his fourth open-market purchase at IVFH; his prior three buys at this ticker all showed positive 90-day returns (ranging from +14.4% to +24.2%), and across his full cross-ticker track record, all 3 prior buys posted positive 90-day returns with a 100% win rate. The current price of $1.90 sits at the 52-week high, and the stock is up +21.8% over the past 30 days and +39.7% over 90 days—price momentum has already materialized since the December 4 entry. However, the company's fundamentals present tension: annual revenue declined 9.8% year-over-year, it was unprofitable over the most recent full fiscal year, and the P/E of 95 reflects a stretched valuation even at current depressed absolute prices. The timing of this buy—following prior successful accumulations and during a period of strong price appreciation—and the significant size of the position merit scrutiny of whether the director's historical pattern remains reliable amid deteriorating operational trends.

Director Smith Denver Johnson bought 31,250 shares of IVFH at $1.60 on 2024-12-05 ($50.0K); 4th buy in sequence with 100% 90d win rate across track record.

Director Smith Denver Johnson purchased 31,250 shares at $1.60, bringing his post-transaction holdings to 2.78M shares, a net increase of 31,250 shares or +1.1%. This is the fourth open-market buy across his entire trading history, following a pattern of three prior purchases at IVFH in July and August 2023, all of which posted positive 90-day returns (8.3%, 24.2%, 15.4%, and 11.4% respectively). His cross-ticker track record shows an average 30-day return of +11.7% and 90-day return of +15.6% with a 100% win rate over the 90-day measurement window. The stock traded at $1.60 on the purchase date and now stands at $1.75, with recent momentum of +9.4% over 30 days and +28.7% over 90 days. However, the company's fundamentals present a mixed picture: it reported revenue of $17.0M in the latest quarter but was unprofitable over its most recent full fiscal year, with annual revenue contracting -9.8% year-over-year. The elevated P/E of 87.50 and market cap of $89.5M relative to current profitability require scrutiny into whether this accumulated open-market buying reflects confidence in a turnaround or exposure to execution risk in a contracting revenue environment.

Director Gramm Jefferson purchased 350,000 shares of IVFH at $1.20 on 2024-07-21; holding now 4,943,349 shares. Cluster buy with 2 others in 14 days.

Gramm Jefferson, a Director, purchased 350,000 shares at $1.20 on 2024-07-21, increasing his post-transaction holdings to 4,943,349 shares (+7.6% vs pre-transaction holdings). This purchase is part of a cluster pattern, with 2 other insiders also buying within the past 14 days. The timing coincides with positive recent price action (30-day change: +9.8%; 90-day change: +39.6%), though the stock trades at $1.34, which is 4.3% below its 52-week high. The company's fundamentals show declining revenue (annual growth of -9.8%) and full-year net profitability concerns, though the latest quarter posted net income of $1,425,874.00 on revenue of $15,730,113.00. The multi-insider buying activity in a declining-revenue environment warrants observation of whether this reflects contrarian conviction or routine portfolio positioning.

CEO Bennett sells 458,349 shares (-22.4% of holdings) at $1.20; stock at $1.34; prior 4 buys at IVFH all well-timed at 90-day mark.

Chief Executive Officer Bennett Robert William sold 458,349 shares of INNOVATIVE FOOD HOLDINGS INC at $1.20 on 2024-07-23, reducing his holdings from 2,041,749 shares to 1,583,400 shares—a 22.4% reduction. This sale occurs against a backdrop of recent price strength: the stock is up 9.8% over 30 days and 39.6% over 90 days, trading at $1.34 today (4.3% below its 52-week high of $1.40). Notably, Bennett's prior four open-market transactions at IVFH were all purchases, and all four demonstrated well-timed entry points with positive 90-day returns (ranging from +1.7% to +19.3%), establishing a pattern of favorable timing on the buy side. The company's fundamentals present headwinds: annual revenue declined 9.8% year-over-year, and despite a positive latest quarter ($1.4M net income on $15.7M revenue), the company was unprofitable over its most recent full fiscal year. The timing and scale of this sale—a 22.4% reduction at an elevated price after sustained gains—contrasts sharply with the insider's prior purchase pattern and merits investor scrutiny of whether this signals confidence-shifting or opportunistic rebalancing at an inflection point.

Director Hank Cohn sold 1,600,000 shares of IVFH at $1.20, reducing stake 51.2% from 3,125,000 to 1,525,000 shares.

Cohn executed a substantial disposal of 1,600,000 shares (1.60M shares) valued at $1,920,000.00 ($1.9M), cutting his holdings by more than half from 3,125,000 shares (3.12M shares) to 1,525,000 shares (1.52M shares). This occurs in a stock trading near its 52-week high of $1.40—the transaction at $1.20 represents a 4.3% discount to that peak, but the stock has appreciated 9.8% over the prior 30 days and 39.6% over 90 days. The company's fundamentals present a mixed picture: while the latest quarter showed revenue of $15,730,113.00 ($15.7M) and net income of $1,425,874.00 ($1.4M), annual revenue declined 9.8% year-over-year and the company was unprofitable over its most recent full fiscal year. A director reducing his position by over half deserves scrutiny, particularly given the recent price momentum and the company's deteriorating revenue trajectory.